Slovenia hub targets $320 billion drug market

Most Europeans have never heard of biosimilars, but they will. Over the next decade, biologic medicines worth roughly USD 320 billion in annual sales will lose patent protection (Apotheke Adhoc, Deutsche Börse / Sandoz release). These are the advanced treatments used for cancer, rheumatic disease, diabetes and immune disorders. Cheaper follow-on versions can save public health systems billions, but only if they arrive on time and at scale.

On 17 June, Sandoz and its Slovenian subsidiary Lek opened a USD 99 million biosimilar development centre in Ljubljana, a 10,000-square-metre facility employing more than 200 scientists (Deutsche Börse / Sandoz release, Office of the President of Slovenia). It is the first completed piece of a broader USD 1.1 billion investment plan to build an end-to-end European biosimilar hub across three Slovenian sites, with production facilities planned in Lendava and Brnik (MarketScreener, finanzen.ch). The figures are company-sourced, even where republished by financial outlets. Still, they describe a serious industrial commitment at a moment when Europe is asking hard questions about pharmaceutical sovereignty.

Why copying a medicine takes a laboratory, not a photocopy machine

An ordinary generic copies a simple chemical molecule, aspirin or metformin, that can be described atom by atom and tested for equivalence in a straightforward way. Biologics are a different animal: they are large, intricate proteins manufactured inside living cells. Think of the difference between reproducing a measured recipe and reproducing a complex fermentation, where the living system, temperature control, purification steps and testing all shape the final product.

The result is that two biosimilars can be clinically equivalent without being exact molecular clones. The European Medicines Agency defines a biosimilar as a biological medicine "highly similar" to an approved reference product, with "no clinically meaningful differences" in quality, safety or efficacy (EMA overview). That regulatory standard is rigorous. Independent research confirms the basic science: living-system production introduces natural variability, but the comparability process is designed to catch anything that matters for patients (PubMed, EMA guide).

What Ljubljana does is the upstream work: refining cell lines, designing formulations, running analytical comparisons against reference medicines, and assembling the evidence packages that regulators later evaluate. It does not produce finished medicines for pharmacies. That distinction matters for expectations.

The savings are real, but conditional

When biosimilars reach the market, the budget effects can be large. NHS England estimated that adalimumab biosimilars alone would save around GBP 300 million per year, on top of roughly GBP 210 million already saved from earlier biosimilar switches (NHS England). In Germany, AOK estimated that proposed limits on rebate contracts could cost statutory insurers about EUR 500 million in short-term savings (krankenkassen-direkt). The European Commission identifies biosimilars as a tool for affordable medicines and sustainable health budgets (European Commission).

These savings, though, depend on national procurement design, physician confidence, substitution rules and the number of competing suppliers. The EMA and Heads of Medicines Agencies now say EU-approved biosimilars are scientifically interchangeable, but each member state still decides its own switching and substitution policies (EMA). Two patients in different EU countries can have very different access to the same approved medicine.

Europe's policy contradiction

The deeper tension runs through Brussels. Europe wants more domestic pharmaceutical capacity. The Commission's reform aims to improve access, strengthen supply security and keep production on the continent (European Commission). At the same time, some tools designed to attract investment risk delaying biosimilar competition. EU ministers remain split over monopoly-extension provisions in the Biotech Act, a proposed law meant to boost Europe's life-sciences industry that also extends how long originator drugs can block competitors. Several governments warn that extra protection could raise costs for health systems (Euronews). German social insurers estimated the potential cost at roughly EUR 1.7 billion annually across the EU if biosimilar entry is delayed by extended protections (DSV Europa).

The reform does include counterweights. A broadened Bolar exemption lets biosimilar developers conduct studies, submit regulatory files and even prepare for tenders before patent protection expires, aiming for day-one market launch once it does (European Parliament, Bird & Bird BioTalk). Whether that balances the pull toward longer monopolies remains an open question.

Ljubljana is a bet that Europe will choose competition. The science behind biosimilars is mature, the savings are proven, and a wave of patent expiries is arriving. But a development lab only becomes a public-health gain when regulation, procurement and political will connect the laboratory bench to the hospital bed. That chain is where the real test lies.